Comparative secretome of ovarian serous carcinoma: Gelsolin in the spotlight

  • Authors:
    • Sandra Pierredon
    • Pascale Ribaux
    • Jean‑Christophe Tille
    • Patrick Petignat
    • Marie Cohen
  • View Affiliations

  • Published online on: April 25, 2017     https://doi.org/10.3892/ol.2017.6096
  • Pages: 4965-4973
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Ovarian cancer is one of the most common types of reproductive cancer, and has the highest mortality rate amongst gynecological cancer subtypes. The majority of ovarian cancers are diagnosed at an advanced stage, resulting in a five‑year survival rate of ~30%. Early diagnosis of ovarian cancer has improved the five‑year survival rate to ≥90%, thus the current imperative requirement is to identify biomarkers that would allow the early detection, diagnosis and monitoring of the progression of the disease, or of novel targets for therapy. In the present study, secreted proteins from purified ovarian control, benign and cancer cells were investigated by mass spectrometry, in order to identify novel specific markers that are easy to quantify in patients sera. A total of nine proteins revealed significant differential secretion from control and benign cells, in comparison with ovarian cancer cells. The mRNA expression levels of three of these proteins (Dickkopf protein 3, heat shock protein 10 kDa and gelsolin) were subsequently evaluated by reverse transcription‑quantitative polymerase chain reaction. Combined with the protein level in serum, the present study identified that gelsolin may be a useful marker of ovarian cancer.
View Figures
View References

Related Articles

Journal Cover

June-2017
Volume 13 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Pierredon S, Ribaux P, Tille JC, Petignat P and Cohen M: Comparative secretome of ovarian serous carcinoma: Gelsolin in the spotlight. Oncol Lett 13: 4965-4973, 2017
APA
Pierredon, S., Ribaux, P., Tille, J., Petignat, P., & Cohen, M. (2017). Comparative secretome of ovarian serous carcinoma: Gelsolin in the spotlight. Oncology Letters, 13, 4965-4973. https://doi.org/10.3892/ol.2017.6096
MLA
Pierredon, S., Ribaux, P., Tille, J., Petignat, P., Cohen, M."Comparative secretome of ovarian serous carcinoma: Gelsolin in the spotlight". Oncology Letters 13.6 (2017): 4965-4973.
Chicago
Pierredon, S., Ribaux, P., Tille, J., Petignat, P., Cohen, M."Comparative secretome of ovarian serous carcinoma: Gelsolin in the spotlight". Oncology Letters 13, no. 6 (2017): 4965-4973. https://doi.org/10.3892/ol.2017.6096